US5798091A
(en)
|
1993-07-30 |
1998-08-25 |
Alliance Pharmaceutical Corp. |
Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
|
ES2231775T5
(es)
|
1993-07-30 |
2011-02-02 |
Imcor Pharmaceutical Co. |
Composición de microburbujas estabilizadas para ecografía.
|
US5540909A
(en)
*
|
1994-09-28 |
1996-07-30 |
Alliance Pharmaceutical Corp. |
Harmonic ultrasound imaging with microbubbles
|
CA2232390A1
(fr)
*
|
1995-09-20 |
1997-03-27 |
University Of Massachusetts |
Chimiotherapie par les oligonucleotides antisens de l'hyperplasie ou du cancer de la prostate
|
US20030143204A1
(en)
*
|
2001-07-27 |
2003-07-31 |
Lewis David L. |
Inhibition of RNA function by delivery of inhibitors to animal cells
|
US6057156A
(en)
|
1997-01-31 |
2000-05-02 |
Robozyme Pharmaceuticals, Inc. |
Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
|
US6969601B2
(en)
*
|
1997-04-03 |
2005-11-29 |
Jensenius Jens Chr |
MASP-2, a complement-fixing enzyme, and uses for it
|
US5914269A
(en)
|
1997-04-04 |
1999-06-22 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide inhibition of epidermal growth factor receptor expression
|
US6586661B1
(en)
*
|
1997-06-12 |
2003-07-01 |
North Carolina State University |
Regulation of quinolate phosphoribosyl transferase expression by transformation with a tobacco quinolate phosphoribosyl transferase nucleic acid
|
US7052692B1
(en)
|
1997-09-02 |
2006-05-30 |
Advanced Research & Technology Institute |
Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
AU5154999A
(en)
|
1998-06-10 |
1999-12-30 |
Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh |
A method for stimulating the immune system
|
SI1119349T1
(sl)
*
|
1998-08-18 |
2008-12-31 |
Univ California |
Antagonisti receptorja epidermalnega rastnega faktorja za zdravljenje hipersekrecije sluzi v pljučah
|
US7094533B1
(en)
*
|
1999-01-21 |
2006-08-22 |
Board Of Regents Of The University Of Nebraska |
Therapeutic and diagnostic applications of prostatic acid phosphatase in prostate cancer
|
EP1165771A2
(fr)
*
|
1999-03-17 |
2002-01-02 |
The University Of Tennessee Research Corporation |
Rt-pcr de neurospheres clonales
|
DE19926216A1
(de)
*
|
1999-06-09 |
2001-02-22 |
Metallgesellschaft Ag |
Verfahren zur Herstellung von Bariumsulfat, Bariumsulfat und Verwendung des Bariumsulfats
|
US7662793B2
(en)
*
|
1999-06-18 |
2010-02-16 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from a Pol III promoter
|
US6787136B1
(en)
*
|
1999-09-03 |
2004-09-07 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
EP1133988A1
(fr)
*
|
2000-03-11 |
2001-09-19 |
Biognostik Gesellschaft für biomolekulare Diagnostik mbH |
Mélange comprenant un inhibiteur ou suppresseur d'un gène et une molécule se liant à un produit d'expression de ce gène
|
EP1319069B1
(fr)
|
2000-06-28 |
2008-05-21 |
Corixa Corporation |
Compositions et methodes pour le traitement et le diagnostic du cancer du poumon
|
KR20030029885A
(ko)
*
|
2000-08-30 |
2003-04-16 |
노쓰 캐롤라이나 스테이트 유니버시티 |
단백질 함량을 변화시키는 분자 미끼를 포함하는유전자이식 식물
|
US6444465B1
(en)
*
|
2000-09-29 |
2002-09-03 |
Isis Pharmaceuticals, Inc. |
Antinsense modulation of Her-1 expression
|
AU2002230691A1
(en)
*
|
2000-11-07 |
2002-05-21 |
North Carolina State University |
Putrescine-n-methyltransferase promoter
|
JP2005504513A
(ja)
|
2001-05-09 |
2005-02-17 |
コリクサ コーポレイション |
前立腺癌の治療及び診断のための組成物及び方法
|
EA200400013A1
(ru)
*
|
2001-06-08 |
2004-06-24 |
Вектор Тобакко Лтд. |
Модификация содержания никотина и нитрозамина в табаке
|
US20060157072A1
(en)
*
|
2001-06-08 |
2006-07-20 |
Anthony Albino |
Method of reducing the harmful effects of orally or transdermally delivered nicotine
|
US7101995B2
(en)
*
|
2001-08-27 |
2006-09-05 |
Mirus Bio Corporation |
Compositions and processes using siRNA, amphipathic compounds and polycations
|
ES2405405T3
(es)
|
2001-12-17 |
2013-05-31 |
Corixa Corporation |
Composiciones y procedimientos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
|
AU2003230833A1
(en)
*
|
2002-04-09 |
2003-10-27 |
Vector Tobacco Ltd. |
Tobacco having reduced nicotine and nitrosamines
|
CA2498264A1
(fr)
*
|
2002-09-09 |
2004-05-13 |
Nura, Inc. |
Recepteurs couples a la proteine g et leurs utilisations
|
US20080260744A1
(en)
|
2002-09-09 |
2008-10-23 |
Omeros Corporation |
G protein coupled receptors and uses thereof
|
US8722872B2
(en)
*
|
2002-10-02 |
2014-05-13 |
The University Of British Columbia |
Compositions and methods for treatment of prostate and other cancers
|
DE60332363D1
(de)
*
|
2002-10-02 |
2010-06-10 |
Univ British Columbia |
Oligonucleotide zur behandlung von prostatakrebs und anderen krebserkrankungen
|
PT2374819T
(pt)
|
2003-05-12 |
2017-07-04 |
Helion Biotech Aps |
Anticorpos para masp-2
|
EP1493445A1
(fr)
*
|
2003-07-04 |
2005-01-05 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Inhibition de l'activation de l'EGFR, cette activation étant dépendante d'un ligand et étant induite par le stress
|
US20050287668A1
(en)
*
|
2003-11-04 |
2005-12-29 |
Cell Therapeutics, Inc. (Cti) |
RNA interference compositions and screening methods for the identification of novel genes and biological pathways
|
US7455840B2
(en)
*
|
2003-11-19 |
2008-11-25 |
The Scripps Research Institute |
Compositions and methods to reduce mutagenesis
|
US8815599B2
(en)
|
2004-06-01 |
2014-08-26 |
Pronai Therapeutics, Inc. |
Methods and compositions for the inhibition of gene expression
|
US8840893B2
(en)
|
2004-06-10 |
2014-09-23 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
US7919094B2
(en)
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
PL2465534T3
(pl)
|
2004-06-10 |
2017-08-31 |
Omeros Corporation |
Sposoby leczenia stanów związanych z aktywacją dopełniacza zależną od masp-2
|
WO2005123776A1
(fr)
*
|
2004-06-10 |
2005-12-29 |
Omeros Corporation |
Procédés servant à traiter des affections associées à l'activation du complément dépendant de la lectine
|
JP2006315017A
(ja)
*
|
2005-05-11 |
2006-11-24 |
Canon Inc |
レーザ切断方法および被切断部材
|
WO2007064857A2
(fr)
*
|
2005-12-01 |
2007-06-07 |
Pronai Therapeutics, Inc. |
Formulation de liposomes amphoteres
|
US20120208824A1
(en)
|
2006-01-20 |
2012-08-16 |
Cell Signaling Technology, Inc. |
ROS Kinase in Lung Cancer
|
HUE039085T2
(hu)
|
2006-01-20 |
2018-12-28 |
Cell Signaling Technology Inc |
Transzlokáció és mutáns ROS kináz humán nem-kissejtes tüdõ karcinómában
|
ES2637592T3
(es)
|
2006-04-14 |
2017-10-13 |
Cell Signaling Technology, Inc. |
Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
|
JPWO2008105441A1
(ja)
*
|
2007-02-27 |
2010-06-03 |
味の素株式会社 |
リン吸収抑制活性を有するポリアミノ酸化合物及びリン吸収抑制剤
|
WO2008106781A1
(fr)
*
|
2007-03-05 |
2008-09-12 |
The University Of British Columbia |
Traitement d'un carcinome de cellules squameuses par des oligonucléotides antisens hsp27 et une radiothérapie
|
US20080260643A1
(en)
|
2007-03-27 |
2008-10-23 |
Omeros Corporation |
Use of pde7 inhibitors for the treatment of movement disorders
|
DK2203558T3
(en)
|
2007-10-18 |
2016-06-27 |
Cell Signaling Technology Inc |
TRANSLOCATION AND mutant ROS kinase IN HUMAN NON-small cell lung carcinoma
|
EP2231195B1
(fr)
|
2007-12-04 |
2017-03-29 |
Arbutus Biopharma Corporation |
Lipides de ciblage
|
WO2009086558A1
(fr)
|
2008-01-02 |
2009-07-09 |
Tekmira Pharmaceuticals Corporation |
Compositions et procédés améliorés pour la délivrance d'acides nucléiques
|
US8058069B2
(en)
|
2008-04-15 |
2011-11-15 |
Protiva Biotherapeutics, Inc. |
Lipid formulations for nucleic acid delivery
|
CN104119242B
(zh)
|
2008-10-09 |
2017-07-07 |
泰米拉制药公司 |
改善的氨基脂质和递送核酸的方法
|
CA3039251C
(fr)
|
2008-11-10 |
2024-01-09 |
Arbutus Biopharma Corporation |
Nouveaux lipides et nouvelles compositions pour l'administration d'agents therapeutiques
|
CA2751342C
(fr)
|
2009-01-29 |
2019-05-07 |
Alnylam Pharmaceuticals, Inc. |
Formules lipides renfermant un lipide cationique et un lipide cible renfermant de la galactosamine n-acetyle pour la livraison d'acide nucleique
|
EP2396342B1
(fr)
|
2009-02-12 |
2014-09-17 |
Cell Signaling Technology, Inc. |
Expression de la protéine mutante ros dans les cancers du foie chez l'être humain
|
CA3045126A1
(fr)
|
2009-05-05 |
2010-11-11 |
Arbutus Biopharma Corporation |
Procedes d'administration d'oligonucleotides en direction de cellules immunitaires
|
SG10201911942UA
(en)
|
2009-05-05 |
2020-02-27 |
Muthiah Manoharan |
Lipid compositions
|
LT2440183T
(lt)
|
2009-06-10 |
2018-08-10 |
Arbutus Biopharma Corporation |
Patobulinta lipido kompozicija
|
ES2613498T3
(es)
|
2009-07-01 |
2017-05-24 |
Protiva Biotherapeutics Inc. |
Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
|
KR101788040B1
(ko)
*
|
2009-10-16 |
2017-10-19 |
오메로스 코포레이션 |
Masp-2 의존성 보체 활성화의 억제에 의한 파종성 혈관내 응고의 치료 방법
|
CA3044884A1
(fr)
|
2009-12-07 |
2011-06-16 |
Arbutus Biopharma Corporation |
Compositions utilisees pour l'administration d'acides nucleiques
|
ES2749426T3
(es)
|
2009-12-18 |
2020-03-20 |
Univ British Columbia |
Métodos y composiciones para administración de ácidos nucleicos
|
US8877188B2
(en)
|
2010-05-04 |
2014-11-04 |
The Brigham And Women's Hospital, Inc. |
Detection and treatment of non-dermal fibrosis
|
US20130202652A1
(en)
|
2010-07-30 |
2013-08-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
WO2012016184A2
(fr)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Procédés et compositions pour la délivrance d'agents actifs
|
WO2012019132A2
(fr)
|
2010-08-06 |
2012-02-09 |
Cell Signaling Technology, Inc. |
Kinase des lymphomes anaplasiques dans le cancer du rein
|
KR20130124333A
(ko)
|
2010-11-08 |
2013-11-13 |
오메로스 코포레이션 |
Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
|
US9220715B2
(en)
|
2010-11-08 |
2015-12-29 |
Omeros Corporation |
Treatment of addiction and impulse-control disorders using PDE7 inhibitors
|
CA2824526C
(fr)
|
2011-01-11 |
2020-07-07 |
Alnylam Pharmaceuticals, Inc. |
Lipides pegyles et leur utilisation pour une administration de medicament
|
US9644035B2
(en)
|
2011-04-08 |
2017-05-09 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
KR20210021101A
(ko)
|
2011-04-08 |
2021-02-24 |
유니버시티 오브 레스터 |
Masp-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
|
WO2012177595A1
(fr)
|
2011-06-21 |
2012-12-27 |
Oncofactor Corporation |
Compositions et méthodes pour la thérapie et le diagnostic du cancer
|
EP3456317A1
(fr)
|
2011-09-27 |
2019-03-20 |
Alnylam Pharmaceuticals, Inc. |
Lipides di-aliphatiques pegylés substitués
|
EP3988104A1
(fr)
|
2012-02-24 |
2022-04-27 |
Arbutus Biopharma Corporation |
Lipides cationiques de trialkyle et leurs procédés d'utilisation
|
PL2838998T3
(pl)
|
2012-04-18 |
2018-04-30 |
Cell Signaling Technology, Inc. |
EGFR i ROS1 w nowotworze
|
WO2014018375A1
(fr)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 et ses utilisations dans des méthodes thérapeutiques et diagnostiques
|
SG11201507211YA
(en)
*
|
2013-03-11 |
2015-10-29 |
Univ North Carolina |
Compositions and methods for targeting o-linked n-acetylglucosamine transferase and promoting wound healing
|
CA3177846A1
(fr)
|
2013-07-11 |
2015-01-15 |
Alnylam Pharmaceuticals, Inc. |
Conjugues ligands d'oligonucleotides et procede pour leur preparation
|
IL283373B1
(en)
|
2013-10-17 |
2024-04-01 |
Omeros Corp |
Pharmaceutical preparations containing MASP-2 suppressors to suppress MASP-2-dependent complement activation and related diseases
|
US11097005B2
(en)
|
2014-12-15 |
2021-08-24 |
The Brigham And Women's Hospital, Inc. |
Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
|
IL295200A
(en)
|
2015-11-09 |
2022-10-01 |
Omeros Corp |
Preparations containing antibodies that suppress masp-2 and antigen-binding fragments for use in the treatment of plasma-resistant ahus
|
MY194810A
(en)
|
2016-01-05 |
2022-12-16 |
Omeros Corp |
Methods for inhibiting fibrosis in a subject in need thereof
|
US9758786B2
(en)
|
2016-02-09 |
2017-09-12 |
Autotelic, Llc |
Compositions and methods for treating pancreatic cancer
|
CN117582494A
(zh)
|
2016-03-31 |
2024-02-23 |
奥默罗斯公司 |
抑制有需要的受试者的血管发生的方法
|
TW202402809A
(zh)
|
2017-08-15 |
2024-01-16 |
美商歐米諾斯公司 |
用於治療和/或預防與造血幹細胞移植有關的移植物抗宿主病和/或瀰漫性肺泡出血和/或靜脈閉塞性病的方法
|
US11584714B2
(en)
|
2018-05-29 |
2023-02-21 |
Omeros Corporation |
MASP-2 inhibitors and methods of use
|
ES2918001A2
(es)
|
2019-08-14 |
2022-07-13 |
Acuitas Therapeutics Inc |
Nanoparticulas lipidicas mejoradas para el suministro de acidos nucleicos
|
JP2023504541A
(ja)
|
2019-12-04 |
2023-02-03 |
オメロス コーポレーション |
Masp-2阻害剤および使用方法
|
US11807641B2
(en)
|
2019-12-04 |
2023-11-07 |
Omeros Corporation |
MASP-2 inhibitors and methods of use
|
IL310547A
(en)
|
2021-08-05 |
2024-03-01 |
Sanegene Bio Usa Inc |
Alkyl substituted ribose derivatives in the '1 position and methods of use
|
CA3229661A1
(fr)
|
2021-09-01 |
2023-03-09 |
Xiang Li |
Composes et procedes pour sauter l'exon 44 dans la dystrophie musculaire de duchenne
|
EP4405368A1
(fr)
|
2021-09-22 |
2024-07-31 |
Sanegene Bio USA Inc. |
Dérivés de ribose modifiés par 2'-alkyle ou 3'-alkyle destinés à être utilisés dans l'administration in vivo d'oligonucléotides
|
CA3233836A1
(fr)
|
2021-10-05 |
2023-04-13 |
Weimin Wang |
Derives de cyclopentane polyhydroxyles et procedes d'utilisation
|
WO2023144798A1
(fr)
|
2022-01-31 |
2023-08-03 |
Genevant Sciences Gmbh |
Lipides cationiques ionisables pour nanoparticules lipidiques
|
WO2023164464A1
(fr)
|
2022-02-22 |
2023-08-31 |
Sanegene Bio Usa Inc. |
Dérivés de ribonucléotides carbocycliques modifiés en position 5' et procédés d'utilisation
|
WO2024015796A1
(fr)
|
2022-07-11 |
2024-01-18 |
Sanegene Bio Usa Inc. |
Dérivés du ribose modifié en 2' optimisés et procédés d'utilisation
|
WO2024038089A1
(fr)
|
2022-08-18 |
2024-02-22 |
Mitodicure Gmbh |
Utilisation d'un agent thérapeutique ayant une activité inhibitrice de phosphodiestérase-7 pour le traitement et la prévention de maladies associées à la fatigue, à l'épuisement et/ou à l'intolérance à l'effort chroniques
|
WO2024042160A1
(fr)
|
2022-08-26 |
2024-02-29 |
Mitodicure Gmbh |
Utilisation d'un agent thérapeutique ayant une activité inhibitrice de l'antiport sodium-hydrogène 1 pour le traitement et la prévention de maladies associées à la fatigue chronique, à l'épuisement et/ou à l'intolérance à l'effort
|